Development of (225)Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

BACKGROUND: The development of radiopharmaceuticals containing 225Ac for targeted alpha therapy is an active area of academic and commercial research worldwide. OBJECTIVES: Despite promising results from recent clinical trials, 225Ac-radiopharmaceutical development still faces significant challenges...

Descripción completa

Detalles Bibliográficos
Autores principales: Robertson, Andrew Kyle Henderson, Ramogida, Caterina Fortunata, Schaffer, Paul, Radchenko, Valery
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249690/
https://www.ncbi.nlm.nih.gov/pubmed/29658444
http://dx.doi.org/10.2174/1874471011666180416161908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249690/
https://www.ncbi.nlm.nih.gov/pubmed/29658444
http://dx.doi.org/10.2174/1874471011666180416161908

Ejemplares similares